GNMX Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF
Quote as of Oct 23, 2026 16:46 UTC · Quotes are refreshed hourly from the data provider, so during market hours a price can be up to about 1–2 hours old; each quote shows its own timestamp.
| Previous Close | 36.51 | Day Range | 36.18 – 36.20 |
| 52-Week Range | 23.88 – 39.65 | Volume | 1.21K |
| Avg Volume | 1.73K | AUM | $1.3M (Oct 24, 2026) |
| Expense Ratio | 0.35% | Yield (TTM) | — |
| NAV | 36.52 | Premium/Discount | -0.92% indicative |
| Inception | May 05, 2026 | Holdings | 59 |
| Issuer | Corgi Funds | Exchange | CBOE |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 218946846 | ISIN | US2189468463 |
| Management | Not stated in source data | ||
About this ETF
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Description from the fund data provider · profile as of Oct 24, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +1.51% | +17.81% | — | — | — | — | — | — | +18.27% |
| Total return | +1.51% | +17.81% | — | — | — | — | — | — | +18.27% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 16, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.35% | Annual cost of a $10,000 investment | $35.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings list retrieved Oct 23, 2026 · The data provider's latest disclosed portfolio for this fund. Issuers publish holdings daily or monthly, so the portfolio date can be earlier; holdings are not live positions. 59 holdings stored, 25 shown.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Moderna Inc | MRNA | 9.21% | 581 | $117.7K |
| 2 | Thermo Fisher Scientific Inc | TMO | 8.89% | 168 | $113.7K |
| 3 | Vertex Pharmaceuticals Inc | VRTX | 6.16% | 147 | $78.7K |
| 4 | Illumina Inc | ILMN | 4.87% | 231 | $62.2K |
| 5 | Guardant Health Inc | GH | 3.48% | 273 | $44.5K |
| 6 | Genmab A/S | GMAB | 3.33% | 1.06K | $42.6K |
| 7 | Revolution Medicines Inc | RVMD | 3.19% | 217 | $40.7K |
| 8 | Iovance Biotherapeutics Inc | IOVA | 3.15% | 2.85K | $40.3K |
| 9 | 10X Genomics Inc | TXG | 3.09% | 567 | $39.5K |
| 10 | Incyte Corp | INCY | 2.69% | 294 | $34.4K |
| 11 | First American Government Obligations Fund… | — | 2.60% | 33.21K | $33.2K |
| 12 | Alnylam Pharmaceuticals Inc | ALNY | 2.49% | 140 | $31.8K |
| 13 | Twist Bioscience Corp | TWST | 2.30% | 217 | $29.4K |
| 14 | Bio-Techne Corp | TECH | 2.19% | 385 | $28.0K |
| 15 | QIAGEN NV | QGEN | 2.15% | 546 | $27.4K |
| 16 | GRAIL Inc | GRAL | 2.09% | 210 | $26.7K |
| 17 | CareDx Inc | CDNA | 2.05% | 378 | $26.1K |
| 18 | BioMarin Pharmaceutical Inc | BMRN | 1.95% | 441 | $25.0K |
| 19 | Krystal Biotech Inc | KRYS | 1.75% | 70 | $22.4K |
| 20 | Tempus AI Inc | TEM | 1.64% | 329 | $21.0K |
| 21 | Adaptive Biotechnologies Corp | ADPT | 1.58% | 826 | $20.2K |
| 22 | Caris Life Sciences Inc | CAI | 1.39% | 560 | $17.8K |
| 23 | Veracyte Inc | VCYT | 1.34% | 371 | $17.1K |
| 24 | NeoGenomics Inc | NEO | 1.31% | 1.02K | $16.8K |
| 25 | Arrowhead Pharmaceuticals Inc | ARWR | 1.31% | 287 | $16.7K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | — | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | — | Last payment | — |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
No distributions in our database for this fund; it may not pay them, or history has not loaded yet.
Risk Statistics
| Volatility 1Y / 3Y | 34.31% / 34.31% | Sharpe 1Y / 3Y | 3.01 / 3.01 |
| Max drawdown 1Y / 3Y | -9.03% / -9.03% | Sortino 1Y | 5.29 |
| Beta vs S&P 500 (3Y) | 2.27 | Correlation vs S&P 500 (1Y) | 0.29 |
| Downside deviation 1Y | 19.55% | Risk-free rate used | 4.04% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 25, 2026. Formulas →
Liquidity
| Volume today | 1.21K | Average volume | 1.73K |
| AUM | $1.3M | Premium/Discount | -0.92% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Week | -$25.4K | -1.95% | $1.3M → $1.3M |
| 1 Month | -$1.4M | -50.60% | $2.8M → $1.3M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for GNMX
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.